I had no idea this could happen. I wouldn’t have done it,” New Jersey-based former Mounjaro user James Norris, who is now visually impaired, told The Post ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on ...

While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...

The makers of two popular weight-loss drugs—Wegovy and Zepbound—are cutting prices to make the medications more affordable ...

The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more af ...

Adults with obesity who have a prescription for Wegovy but do not have insurance coverage for the drug can now purchase the ...

From STAT’s Elaine Chen: A federal judge this week ruled against a compounding trade group that wanted to continue making ...

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...

Hims & Hers Health's revenue grew 69% YoY, boosting its outlook. See why HIMS stock’s growth potential and high implied ...

According to Halozyme, the new version of Keytruda infringes on its patents, the report said. USAID cuts put tuberculosis response in peril, WHO says The Trump administration's decision to pause U.S.

The federal government has spent $6.2 billion on research and development for weight-loss drugs. Now, thanks to Big Pharma ...